Cizzle Biotechnology New Research Agreement with the University of York for Cancer Tests

Cizzle Biotechnology Holdings

Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, is pleased to announce that it has entered into a new research agreement with the University of York for the development and validation of molecular tools with potential applications in cancer diagnosis and therapy.

The Company’s wholly owned subsidiary Cizzle Biotechnology Limited was a spin out from the University of York based on original research and development undertaken in laboratories at the University, under the direction of Professor Dawn Coverley. The new agreement extends that relationship and provides seconded staff and access to the University’s state of the art research facilities to support reagent generation work in collaboration with our recently announced Contract Research Organisation (CRO) partner Fairjouney Biologics.

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: “We are thrilled to be able to cement our long-standing relationship with the University of York, a member of the Russell Group of research-intensive universities and one of the world’s premier institutions for inspirational and life-changing research.  This new agreement will provide valuable additional resource and capability for developing our blood test for the early detection of lung cancer, and potentially other forms of cancer.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Cizzle Biotechnology raises £150k to support cancer test rollout

    Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe.

    Cizzle Bio expands into Caribbean with first contract, secures early royalties

    Cizzle Biotechnology announces significant strides in early lung cancer detection through its partner's first Caribbean contract, boosting its biomarker test rollout.

    Cizzle Biotechnology launches its new corporate website

    Cizzle Biotechnology Holdings plc has launched a new corporate website, enhancing access to vital information about its early cancer tests and growth strategy.

    Cizzle Biotechnology appoints Matt Bower as a Non-Executive Director

    Cizzle Biotechnology appoints Matt Bower as Non-Executive Director, enhancing its board for growth as it prepares to launch innovative cancer tests globally.

    Cizzle Bio appoints iGenomeDX to launch CIZ1B biomarker test in USA

    Cizzle Biotechnology announces a breakthrough in early lung cancer detection with iGenomeDX appointed to launch the CIZ1B biomarker test across the USA.

    Cizzle Biotechnology appoints Professor Dawn Coverley as Chief Scientific Officer

    Cizzle Biotechnology names Professor Dawn Coverley as Chief Scientific Officer, marking a strategic shift. She will focus on advancing the CIZ1B biomarker assay.

      Search

      Search